Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Company profile
Ticker
ETTX
Exchange
Website
CEO
Manoussos Perros
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Entasis Therapeutics Ltd
SEC CIK
Corporate docs
Subsidiaries
Entasis Therapeutics Inc. • Entasis Therapeutics Limited • Entasis Therapeutics Security Corporation • Entasis Therapeutics (Ireland) Limited ...
ETTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 22
Latest ownership filings
4
Change in insider ownership
13 Jul 22
SC 13D/A
Innoviva, Inc.
11 Jul 22
4
Kristie Ann Wagner
11 Jul 22
4
Anna Diaz Triola
11 Jul 22
4
Ruben Tommasi
11 Jul 22
4
Matthew Ronsheim
11 Jul 22
4
Manoussos Perros
11 Jul 22
4
John Patrick Mueller
11 Jul 22
4
David D. Meek
11 Jul 22
4
Howard Mayer
11 Jul 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 33.55 mm | 33.55 mm | 33.55 mm | 33.55 mm | 33.55 mm | 33.55 mm |
| Cash burn (monthly) | (no burn) | 949.17 k | 5.31 mm | 4.63 mm | 4.58 mm | 3.89 mm |
| Cash used (since last report) | n/a | 9.55 mm | 53.41 mm | 46.59 mm | 46.11 mm | 39.09 mm |
| Cash remaining | n/a | 24.00 mm | -19.87 mm | -13.04 mm | -12.57 mm | -5.54 mm |
| Runway (months of cash) | n/a | 25.3 | -3.7 | -2.8 | -2.7 | -1.4 |
Institutional ownership, Q2 2022
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 10 |
| Closed positions | 5 |
| Increased positions | 7 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 141.47 mm |
| Total shares | 64.39 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| INVA Innoviva | 57.35 mm | $125.01 mm |
| Clarus Lifesciences III | 1.34 mm | $3.91 mm |
| Gardner Lewis Asset Management L P | 1.25 mm | $2.75 mm |
| Beryl Capital Management | 1.13 mm | $2.49 mm |
| TPG GP A | 1.02 mm | $2.25 mm |
| Vanguard | 502.62 k | $1.11 mm |
| Susquehanna International | 393.56 k | $866.00 k |
| Renaissance Technologies | 350.35 k | $771.00 k |
| Geode Capital Management | 180.83 k | $397.00 k |
| Deltec Asset Management | 155.61 k | $342.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Jul 22 | Anna Diaz Triola | Common Stock | Sale back to company | Dispose D | No | No | 0 | 125,000 | 0.00 | 0 |
| 11 Jul 22 | Anna Diaz Triola | Stock Option Common Stock | Other | Dispose J | No | No | 2.49 | 100,000 | 249.00 k | 0 |
| 11 Jul 22 | Kristie Ann Wagner | Common Stock | Sale back to company | Dispose D | No | No | 0 | 80,500 | 0.00 | 0 |
| 11 Jul 22 | Kristie Ann Wagner | Stock Option Common Stock | Other | Dispose J | No | No | 2.4 | 73,400 | 176.16 k | 0 |
| 11 Jul 22 | Innoviva | Common Stock | Buy | Acquire P | Yes | No | 2.2 | 7,598,814 | 16.72 mm | 29,270,476 |
| 11 Jul 22 | David Altarac | Common Stock | Sale back to company | Dispose D | No | No | 0 | 150,000 | 0.00 | 0 |
| 11 Jul 22 | David Altarac | Stock Option Common Stock | Other | Dispose J | No | No | 4.94 | 50,000 | 247.00 k | 0 |
| 11 Jul 22 | David Altarac | Stock Option Common Stock | Other | Dispose J | No | No | 2.44 | 92,307 | 225.23 k | 0 |
| 11 Jul 22 | Hastings David C | Common Stock | Sale back to company | Dispose D | No | No | 2.2 | 27,500 | 60.50 k | 0 |
| 11 Jul 22 | Hastings David C | Stock Option Common Stock | Other | Dispose J | No | No | 2.98 | 11,000 | 32.78 k | 0 |